VANDA Pharmaceuticals - Investor Relations - IR Home

Investor Relations

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Vanda Pharmaceuticals Announces Participation at November 2017 Investor Conferences
WASHINGTON , Nov. 13, 2017 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it will participate at the following upcoming investor conferences in November 2017 . The Stifel 2017 Healthcare Conference in New York City on Tuesday, November 14, 2017 .
View HTML
Toggle Summary Vanda Receives Negative Opinion for Marketing Authorization from the European Medicines Agency on Fanaptum™ for the Treatment of Schizophrenia
WASHINGTON , Nov. 10, 2017 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) announced today the refusal of the marketing authorization application (MAA) of Fanaptum™ (oral iloperidone tablets) for the treatment of schizophrenia in adult patients in the European Union .  In July
View HTML
Toggle Summary Vanda Pharmaceuticals Reports Third Quarter 2017 Financial Results
-- Total net product sales were $41.3 million in the third quarter of 2017 -- HETLIOZ® to psychiatrists initiative fully launched in October 2017 -- Tradipitant study showed significant improvement to itch and disease severity in atopic dermatitis -- Vanda is providing an update to its 2017
View HTML
Toggle Summary Vanda Pharmaceuticals to Announce Third Quarter 2017 Financial Results on November 7, 2017
Conference Call and Webcast to Follow WASHINGTON , Oct. 24, 2017 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the third quarter of 2017 on Tuesday, November 7, 2017 , after the market closes.
View HTML
Toggle Summary Vanda Pharmaceuticals Announces Participation at the Oppenheimer Specialty Pharma Summit Conference
WASHINGTON , Oct. 10, 2017 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it will host investor meetings at the Oppenheimer Specialty Pharma Summit Conference in New York City on Wednesday, October 11, 2017 . About Vanda Pharmaceuticals Inc.
View HTML
Toggle Summary Vanda to Present Tradipitant Phase II Atopic Dermatitis Data at World Congress of Itch
WASHINGTON , Oct. 2, 2017 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) today announced that data from the results of the Phase II study of tradipitant in atopic dermatitis will be presented at the 9th World Congress of Itch in Wroclaw Poland as a late breaking entry in the
View HTML
Toggle Summary Vanda to Present Scientific Posters at World Sleep 2017
WASHINGTON , Sept. 29, 2017 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) today announced participation at the 2017 joint congress of World Association of Sleep Medicine and World Sleep Federation (World Sleep 2017) in Prague, Czech Republic in the scientific poster forum on
View HTML
Toggle Summary Vanda´s Tradipitant Improves Itch and Disease Severity in Patients with Atopic Dermatitis
-- Worst Itch Visual Analog Scale (Worst Itch VAS): Tradipitant vs. Placebo p=0.019 -- Scoring Atopic Dermatitis (SCORAD): Tradipitant vs. Placebo p=0.008 Management to host conference call on Thursday, September 14 at 8:30 AM ET WASHINGTON , Sept. 13, 2017 /PRNewswire/ -- Vanda Pharmaceuticals
View HTML
Toggle Summary Vanda Pharmaceuticals Announces Participation at September 2017 Investor Conferences
WASHINGTON , Sept. 11, 2017 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it will participate at the following upcoming investor conferences in September 2017 . The Rodman and Renshaw 19 th Annual Global Investment Conference in New York City on Tuesday,
View HTML
Toggle Summary Vanda Pharmaceuticals Announces Participation at the Citi 12th Annual Biotech Conference
WASHINGTON , Sept. 6, 2017 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it will participate at the Citi 12 th Annual Biotech Conference . Vanda will host meetings at the Citi Biotech Conference in Boston on Thursday, September 7, 2017 .
View HTML
Toggle Summary Vanda Pharmaceuticals Reports Second Quarter 2017 Financial Results
- Total net product sales were $42.1 million in the second quarter of 2017 - Hetlioz® net product sales grew to $22.5 million in the second quarter of 2017 - Fanapt® net product sales grew to $19.5 million in the second quarter of 2017 - Vanda reiterates 2017 net product sales guidance of $165
View HTML
Toggle Summary Vanda Receives Negative Opinion for Marketing Authorization from the European Medicines Agency on Fanaptum™ for the Treatment of Schizophrenia
WASHINGTON , July 21, 2017 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA)  announced today that the European Medicines Agency's Committee for Medicinal Product for Human Use (CHMP) has adopted a negative opinion recommending against the marketing authorization of Fanaptum™ (oral
View HTML
Toggle Summary Vanda Pharmaceuticals to Announce Second Quarter 2017 Financial Results on August 2, 2017
Conference Call and Webcast to Follow WASHINGTON , July 17, 2017 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the second quarter of 2017 on Wednesday, August 2, 2017 , after the market closes.
View HTML
Toggle Summary Vanda Pharmaceuticals Announces Participation at June 2017 Investor Conferences
WASHINGTON , June 5, 2017 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it will participate at the following upcoming investor conferences in June 2017 . The Jefferies 2017 Global Healthcare Conference in New York City on Wednesday, June 7, 2017 .
View HTML
Toggle Summary Vanda Pharmaceuticals Reports First Quarter 2017 Financial Results
- Total net product sales were $37.4 million in the first quarter of 2017 - Vanda reiterates 2017 net product sales guidance of $165 million to $175 million    WASHINGTON , May 2, 2017 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ), today announced financial and operational
View HTML
Toggle Summary Vanda Pharmaceuticals to Present at the Deutsche Bank 42nd Annual Health Care Conference
Presentation will be Webcast Live and Archived on Vanda's Website WASHINGTON , May 1, 2017 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it will deliver a corporate presentation at the Deutsche Bank 42 nd Annual Health Care Conference in Boston,
View HTML
Toggle Summary Vanda Pharmaceuticals to Announce First Quarter 2017 Financial Results on May 2, 2017
WASHINGTON , April 13, 2017 /PRNewswire/ -- Conference Call and Webcast to Follow Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the first quarter of 2017 on Tuesday, May 2, 2017 , after the market closes.
View HTML
Toggle Summary Vanda and UCSF Announce License Agreement for CFTR Activators and Inhibitors
WASHINGTON , March 29, 2017 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) announced today that it has entered into a license agreement with UC San Francisco (UCSF), under which Vanda will acquire an exclusive worldwide license from UCSF to develop and commercialize a portfolio
View HTML
Toggle Summary Vanda Pharmaceuticals Announces Participation at March 2017 Investor Conferences
WASHINGTON , March 6, 2017 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it will participate at the following upcoming investor conferences in March 2017 . The Cowen and Company 37 th Annual Healthcare Conference in Boston on Tuesday, March 7, 2017 .
View HTML
Toggle Summary Vanda Pharmaceuticals Reports Fourth Quarter 2016 and Full Year 2016 Financial Results
- Full year 2016 total revenues grew to $146 million, a 33% increase compared to 2015 WASHINGTON , Feb. 15, 2017 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ), today announced financial and operational results for the fourth quarter and full year ended December 31, 2016 .
View HTML
Toggle Summary Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2016 Financial Results on February 15, 2017
WASHINGTON , Jan. 19, 2017 /PRNewswire/ -- Conference Call and Webcast to Follow Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the fourth quarter of 2016 on Wednesday, February 15, 2017 , after the market closes.
View HTML
Toggle Summary Vanda Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2016 Revenue Results and 2017 Financial Guidance
- 2016 Total revenues are expected to be approximately $146 million - 2017 Total revenues are expected to be between $165 million and $175 million WASHINGTON , Jan. 9, 2017 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and
View HTML
Copyright © 2005-2020 Vanda Pharmaceuticals Inc. |